{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "3af7fbbcfb10d8f739e8f4cdde1f7e35",
    "title": "Eisai (4523)",
    "source_uri": "2025-08-29/Earnings bottom out as Leqembi sales rise but caution on sustained profit growthEarnings bottom out as Leqembi sales ris_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T23:55:30.386455",
      "extracted_at": "2025-10-26T23:55:30.386462"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 13,
        "successful_pages": 13,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 2,
          "reduction_ratio": 0.13734146232922428
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "a16acacb6988e523",
      "text": "Reiterate Rating: UNDERPERFORM | PO: 3,800 JPY | Price: 4,597 JPY",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "150d436b451ae6d8",
      "text": "1Q results confirmed sales growth for Leqembi (Alzheimer's disease therapy) and bottoming earnings, and we revise up our five- year- forward operating profit (OP) estimates by \\(15\\%\\) . Consequently, we lift our price objective (PO) from ¥3,330 to ¥3,800, based on discounted cash flow (DCF). We estimate that earnings will bottom out, but sustained Leqembi sales growth and reductions in cost of goods sold (COGS) will be important, and we intend to monitor these closely in 2Q onwards. We think it will be a while before the indication for the subcutaneous formulation with auto- injector (SC- Al) is expanded to initial administration and for the full- scale uptake of blood- based biomarkers (BBM) as a confirmatory test. We reiterate our Underperform rating.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d68ee7fc1443912b",
      "text": "1Q Leqembi sales were solid, surpassing our estimates globally, even excluding the impact of stockpiling in China. We think that (1) SC- Al approval/launch and (2) the uptake of BBM testing will be important for the company to consistently attain market estimates. For (1), the target US review end- date (PDUFA) for maintenance treatment is 31 August. For (2), US approval of Lumipulse G (Fujirebio) provides support, and we see growing BBM uptake initially as a triage test.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a16de8e8ab3dfafb",
      "text": "Eisai announced the launch of Leqembi in Germany and Australia. Although there were complications, use in the EU is now possible. As far as we can see from 1Q results, Leqembi's COGS ratio may not be particularly high, but growth in the proportion of SC- Al usage will lead to higher COGS, and our focus will be on initiatives to reduce these, including ingenuity in the supply chain.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ff34e81b0ec19c47",
      "text": "Estimates (¥)3/24A3/25A3/26E3/27E3/28EIFRSIFRSIFRSIFRSIFRSIFRSEPS147.90161.94165.23190.34213.71EPS Change (YoY)-23.5%9.5%2.0%15.2%12.3%Consensus EPS (Visible Alpha)169.60203.53251.40Dividend / Share-160160160160BPS3,053.42,934.22,942.12,975.33,031.7ValuationP/E31.1x28.4x27.8x24.2x21.5xDividend Yield*3.5%3.5%3.5%3.5%P/B1.5x1.6x1.6x1.5x1.5xEV/EBITDA*12.9x12.5x12.2x12.0x11.2xFree Cash Flow Yield*2.4%0.5%2.4%1.4%0.3%",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d462d133b6916c57",
      "text": "\\\\* For full definitions of \\(\\sqrt{\\mathrm{right}}\\) measures, see page 10.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8d7f671134a19923",
      "text": ">> Employed by a non- US affiliate of BofAS and is not registered/qualified as a research analyst under the FINRA rules.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d7f27cf5e360574e",
      "text": "Refer to \"Other Important Disclosures\" for information on certain BofA Securities entities that take responsibility for the information herein in particular jurisdictions.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c9d110fffa42984b",
      "text": "BofA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5ebef042a73121b6",
      "text": "Refer to important disclosures on page 11 to 13. Analyst Certification on page 8. Price Objective Basis/Risk on page 8.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "edb6872a32ad925f",
      "text": "Key Changes(V)PreviousCurrentPrice Obj.3,300.003,800.002026E Rev (m)790,700.00797,500.002027E Rev (m)819,900.00828,000.002028E Rev (m)884,900.00890,500.002026E EPS150.58165.232027E EPS166.62190.342028E EPS193.13213.712026E EBITDA (m)95,540.00100,700.002027E EBITDA (m)96,140.00102,800.002028E EBITDA (m)105,240.00109,700.00",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2624c2209bff7792",
      "text": "Stock DataPrice4,597 JPYPrice Objective3,800 JPYDate Established29-Aug-2025Investment OpinionB-3-752-Week Range3,463-6,146 JPYMarket Value (mn)1,317,893 JPYMarket Value (Smn)8,913 USDShares Outstanding (mn)286.7Average Daily Value (Smn)44.2 USDFree Float91.1%BofA Ticker / ExchangeESALF / TYOBloomberg / Reuters4523 JP / 4523.TROE (2026E)5.6%Net Dbt to Eqty (Mar-2025A)-13.4%",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "20b284baa7213541",
      "text": "BBM: Blood- based biomarker",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "50e5e34b33fb02d8",
      "text": "SC- Al: Subcutaneous formulation with Auto- Injector",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1b2d0f363a73ec23",
      "text": "Key Income Statement Data3/24A3/25A3/26E3/27E3/28E(Y Millions)IFRSIFRSIFRSIFRSIFRSSales741,751789,400797,500828,000890,500% Change-0.4%6.4%1.0%3.8%7.5%Gross Profit586,417620,593618,500621,700644,500EBITDA95,20698,568100,700102,800109,700Operating Profit53,40854,37859,80063,70072,100% Change33.4%1.8%10.0%6.5%13.2%Net Interest &amp;amp; Other Income8,4166,6886,7006,6006,500Pretax Income61,82361,06566,50070,30078,600% Change37.3%-1.2%8.9%5.7%11.8%Net Income42,40646,43247,37454,57461,274",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "9c84575598597483",
      "text": "Key Cash Flow Statement Data",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "38578df15de07ecf",
      "text": "Net Income from Cont Operations (GAAP)42,40646,43247,37454,57461,274Depreciation &amp;amp; Amortization41,79844,19040,90039,10037,600Change in Working Capital(27,249)(47,376)(14,000)(32,900)(52,400)Capital Expenditure(24,823)(23,229)(22,969)(22,969)(22,969)Free Cash Flow*31,1726,88231,30517,8053,505Share Issue / (Repurchase)(21)(30,106)000Cost of Dividends Paid(45,915)(45,545)(45,100)(45,100)(45,100)",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "3881c10162c05a3d",
      "text": "Key Balance Sheet Data",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "3692a2e917687067",
      "text": "Cash &amp;amp; Equivalents305,123266,049252,400225,100183,500Trade Receivables217,208220,022224,900235,600255,900Other Current Assets200,652241,588255,800292,200345,000Property, Plant &amp;amp; Equipment164,894158,088146,300136,300127,800Other Non-Current Assets505,922500,800514,500528,400542,300Total Assets1,393,7991,386,5471,393,9001,417,6001,454,500Short-Term Debt34,25015,38515,40015,40015,400Other Current Liabilities270,222356,909361,900376,100396,800Long-Term Debt173,321134,261134,300134,300134,300Other Non-Current Liabilities17,03114,02314,00014,00014,000Total Liabilities494,824520,578525,600539,800560,500Total Equity898,975865,968868,300877,800894,000Total Equity &amp;amp; Liabilities1,393,7991,386,5461,393,9001,417,6001,454,500",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f720fb1d0753ea75",
      "text": "iQ method™ - Business Performance*Return On Capital Employed4.3%4.7%5.0%5.7%6.3%Return On Equity5.1%5.4%5.6%6.4%7.1%Operating Margin7.2%6.9%7.5%7.7%8.1%iQ method™ - Quality of Earnings*Cash Realization Ratio-1.3x0.6x1.1x0.7xAsset Replacement Ratio-1.0x0.9x1.0x1.1xTax Rate (Reported)-29.2%21.3%26.3%20.1%Net Debt-to-Equity Ratio--10.9%-13.4%-11.8%-8.6%Interest Cover-22.4x15.5x17.1x18.2x",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "d9d225eda82c1c36",
      "text": "\\\\* For full definitions of iQmethodTM measures, see page 10. Other GAAP denotes Japanese Accounting Standards.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "2db42705f2ca4cf7",
      "text": "Eisai has a strong presence in the Alzheimer's disease (AD) space and is positioned for its next stage of growth following successful development of AD drug Leqembi. However, cultivation of the AD drug market requires expanding disease awareness and diffusion of simple diagnostic methods such as blood biomarkers, which will take time to realize. Generic competition to another mainstay drug, anticancer agent Lenvima, is likely around 2030 given the recent ANDA litigation settlement.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a683654020546df2",
      "text": "Our Underperform rating is based on the following three points: (1) Uncertainty over the European approval of AD drug Leqembi, (2) intensifying competition from the US approval of Eli Lilly's competing drug Kisunla, and (3) likelihood that it will take time for market penetration of blood biomarkers. Our focus is now on Leqembi sales progress and the rollout of Eli Lilly's Kisunla as there are few catalysts other than life cycle management for Leqembi.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "d8a537ff8d7d1a4d",
      "text": "Exhibit 1: Eisai (4523): Consolidated earnings summary Sales, OP and EPS",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "b2c2b8e6fd847562",
      "text": "Sales¥ mnYoY%OP¥ mnYoY%EBT¥ mnYoY%NP¥ mnYoY%EPS¥PERtimesFY3/25 actualIFRS789,4006454,3781861,065-1.246,4329.5161.928.4Company estimate790,00054,5000.254,500-10.841,500-10.6147.231.2FY3/26 BofA estimateRevised797,5001.059,80010.066,5008.947,3742.0165.227.8Previous790,7000.254,100-0.560,800-0.443,174-7.0150.630.5VA consensus803,9441.861,92213.965,9938.147,8903.1169.627.1FY3/27 BofA estimateRevised828,0003.863,7006.570,3005.754,57415.2190.324.2Previous819,9003.755,2002.061,8001.647,77410.7166.627.6VA consensus848,3655.575,20621.579,29120.257,64820.4203.522.6FY3/28 BofA estimateRevised890,5007.572,10013.278,60011.861,27412.3213.721.5Previous884,9007.964,70017.271,20015.255,37415.9193.123.8VA consensus905,8486.892,94523.697,10622.570,96923.1251.418.3FY3/29 BofA estimateRevised957,2007.586,80020.493,30018.772,97419.1254.518.1Previous954,6007.979,60023.086,10020.967,27421.5234.619.6VA consensus971,0187.2112,82621.4117,10920.685,77320.9302.915.2FY3/30 BofA estimateRevised1,037,9008.4106,20022.4112,70020.888,57421.4308.914.9Previous1,029,8007.993,50017.5100,00016.178,37416.5273.416.8VA consensus1,065,0829.7129,35814.7133,77114.297,90914.1346.913.3",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "118d7e7c618571b5",
      "text": "Source: Company, Visible Alpha. Estimates by BofA Global Research",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "9a7a9993bf80892e",
      "text": "We calculate ¥3,800 price objective based on 12- year DCF",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "28fbdef340f87bd3",
      "text": "FY3/26EFY3/27EFY3/28EFY3/29EFY3/30EFY3/31EFY3/32EFY3/33EFY3/34EFY3/35EFY3/36EFY3/37EUnlevered FCF31,33117,8313,53113,23121,63134,83160,53151,53168,13154,831106,63186,431Terminal FCF73,511A+ B+ C= DWACCFCF NPV (12Y)PV of terminal FCF at perpetuity of 0.5%1.0%1.5%Net Cash FY3/22Present Value of Equity 0.5%1.0%1.5%Equity Value per Share: JPY 0.5%1.5%6.4%342,150608,950668,362739,832134,6621,085,7621,145,1741,216,6446.5%339,816592,413649,219717,326134,6621,066,8921,123,6981,191,8043,7863,9946.6%337,504576,490630,838695,786134,6621,048,6561,103,0041,167,9523,7213,9196.7%335,212561,150613,177675,157134,6621,031,0251,083,0521,145,0323,6573,8466.8%332,942546,365596,198655,386134,6621,013,9691,063,8031,122,9913,5953,777Assumptions:3,5363,710Shares outstanding (k)286,757WACCRisk free rate1.5%Cost of Debt (rate and weight)2.0%14%Market Risk Premium5.5%Cost of Equity (rate and weight)7.4%86%",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "bccc561631f27ece",
      "text": "Quantitative volatilityQuantitative volatilityApplied beta for PO computationFCF risk ratingVery lowLowMediumHighVery highCenter column: Bloomberg 2Y adjusted betaQualitative volatilityHigh-10%0%10%20%30%0.800.890.98Medium-20%-10%0%10%20%0.710.800.89Low-30%-20%-10%0%10%0.620.710.80",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "8f0ad6ea17d6b56c",
      "text": "Source: BofA Global Research estimates. Note: NCV = Net Cash Value. Please refer to our earnings model, available on our Research Library website.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "f4c33ad6f1a60485",
      "text": "Exhibit 3: Income Statement Commercial success of Alzheimer's drug Leqembi is key to sustained growth",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "30c1853b0ea719b2",
      "text": "JPY in millionsIFRSIFRSIFRSIFRSIFRSIFRIFRSIFRSIFRSIFRSIFFiscal year endFY3/24FY3/25FY3/26eFY3/27eFY3/28eFY3/29eFY3/30eFY3/31eFY3/32eFY3/33eGuidanceNet sales741,751789,400797,500828,000890,500957,2001,037,901,111,101,123,701,166,00790,000CoGS155,333168,807179,000206,300246,000284,000323,100360,000379,900405,500182,500Gross profit586,417620,593618,500621,700644,500673,200714,800751,100743,800760,500607,500SG&amp;amp;A (R&amp;amp;D excluded)374,421407,983399,900397,500410,200422,500438,800455,100447,300450,600396,000OP before R&amp;amp;D expense222,429226,011227,100232,700242,800259,200284,500304,500305,000318,400221,000R&amp;amp;D expense169,021171,633167,300169,000170,700172,400178,300184,400190,700197,200166,500Other income11,99817,1579,5009,5009,5009,5009,0009,5009,5009,500Other loss1,5663,7571,0001,0001,0001,0001,1001,0001,0001,000Operating profit53,40854,37859,80063,70072,10086,800106,200120,100114,300121,20054,500Non-op/int. income10,80410,20710,20010,10010,00010,00010,00010,00010,10010,000Non-o/int. expense2,3883,5193,5003,5003,5003,5003,0003,5003,5003,500EBT (Pretax income)61,82361,06566,50070,30078,60093,300112,700126,600120,800127,70054,500Tax provision18,04013,00717,50014,10015,70018,70022,50025,30024,20025,50015,500Minority shareholders income1,3771,6261,6261,6261,6261,6251,6261,6251,6251,6252,000Net income42,40646,43247,40054,60061,30073,00088,60099,70095,000100,60041,500",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "649afbf225769cd8",
      "text": "Margin analysisGross margin79.1%78.6%77.6%75.1%72.4%70.3%68.9%67.6%66.2%65.2%SG&amp;amp;A50.5%51.7%50.1%48.0%46.1%44.1%42.3%41.0%39.8%38.6%R&amp;amp;D22.8%21.7%21.0%20.4%19.2%18.0%17.2%16.6%17.0%16.9%Operating margin7.2%6.9%7.5%7.7%8.1%9.1%10.2%10.8%10.2%10.4%Effective tax rate29.2%21.3%26.3%20.1%20.0%20.0%20.0%20.0%28.4%Net margin5.7%5.9%5.9%6.6%6.9%7.6%8.5%9.0%8.5%8.6%",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "5854bab6e9a88806",
      "text": "% YOY changeNet sales-0.4%6.4%1.0%3.8%7.5%7.5%8.4%7.1%1.1%3.8%Operating profit33.4%1.8%10.0%6.5%13.2%20.4%22.4%13.1%-4.8%6.0%",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9d70f8ef4180f4af",
      "text": "ROE analysisROE5.1%5.4%5.6%6.4%7.1%8.2%9.6%10.2%9.3%9.4%Net income/Net sales5.7%5.9%5.9%6.6%6.9%7.6%8.5%9.0%8.5%8.6%Net sales/Total asset0.560.570.570.590.620.650.680.690.670.68Total asset/Shareholders equity1.591.621.651.661.671.671.671.651.641.62",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "ab492b706d2505d4",
      "text": "Foreign exchangeJPY/USD145153145145145145145145145JPY/Euro151164161160160160160160160",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b1e93c40058e0c00",
      "text": "Source: Company. Estimates by BofA Global Research.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "1a91253de3a3122a",
      "text": "Exhibit 4: Cash Flow Statement & Balance Sheet Aims to create ROE that exceeds cost of capital through financial leverage",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "76fe8ce5f19e818f",
      "text": "JPY in millionIFRSIFRSIFRSIFRSIFRSIFRIFRSIFRSIFRSIFRSIFSIFRSIFRSIFRSIFRSIFRSIFRIFRSIFRSIFRSIFRSIFSIFRSIFRSIFRSIFRSIFRSIFRIFRSIFRSIFRSIFRSIFSIFRSIFRSIFRSIFRSIFRSIFRIFRSIFRSIFRSIFRSIFSIFRSIFRSIFRSIFRSIFRSIFRIFRSIFRSIFRSIFRSIFSIFRSIFRSIFRSIFRSIFRSIFRIFRSIFRSIFRSIFRSIFSIFRSIFRSIFRSIFRSIFRIFRSIFRSIFRSIFRSIFRSIFSIFRSIFRSIFRSIFRSIFRIFRSIFRSIFRSIFRSIFSIFRSIFRSIFRSIFRIFRSIFRSIFRSIFRSIFRIFRIFRSIFRSIFRSIFRIFRSIFRSIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFRIFRIFRIFRSIFRIFRIFRSIFRIFRSIFR",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "8c4f73b9c8540fd7",
      "text": "Exhibit 5:Sales breakdown Focus on market penetration of Alzheimer's agent Leqembi",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "72241f68f40e0c5a",
      "text": "JPY in million Fiscal year endIFRS FY3/24IFRS FY3/25IFRS FY3/26eIFRS FY3/27eIFRS FY3/28eIFRS FY3/29eFY3/30eFY3/31eFY3/32eFY3/33eIFRS GuidancePharmaceutical segment691,500749,000761,980794,332858,489926,7641,008,961,083,571,097,611,141,16754,500Japan216,900216,300226,900241,600256,500272,500295,400323,000310,300327,300225,500North America232,400278,300274,500290,300346,200403,600456,200488,600498,600513,100273,000China111,900115,500125,500136,100141,500142,400147,700155,500163,900169,400124,000Europe76,00079,40072,18060,33251,08947,66451,16160,47871,11479,86871,000East Asia Global South54,20059,60062,90066,00063,20060,60058,50056,00053,70051,50061,000Others segment50,30040,40035,50033,70032,00030,40028,90027,50026,10024,80035,500Lenvima rev. from MRK18,900Other business31,40040,40035,50033,70032,00030,40028,90027,50026,10024,800Consolidated Sales741,751789,400797,500828,000890,500957,2001,037,9001,111,1001,123,7001,166,000790,000Revenues from Merck on Lenvima businessOption incomeSales milestone18,900Total18,900Global productLeqembi (Alzheimer&#x27;s disease)4,20043,50078,400145,300229,000317,700411,800502,000541,800605,70076,500Japan40012,70024,20037,20051,90068,60091,500120,900108,900126,10024,000US3,80026,10036,40075,200132,600195,900250,400290,200321,700351,70040,000EU1,8004,5009,90016,60025,80037,00047,20056,800China etc.4,70016,00028,40034,60036,60044,10053,90064,00071,10012,500Lenvima (cancer)284,700312,900304,600267,500248,500227,300211,200188,600153,600125,300312,000Japan15,50013,90014,30012,9009,1006,5006,2006,2006,2006,20013,000US204,100232,300223,700201,300198,000188,200178,800161,000128,800103,000217,500EU38,20041,90041,10032,90023,00016,00011,3008,0006,5005,20041,000China26,90024,80025,50020,40018,40016,60014,90013,40012,10010,90025,000East Asia Global South13,00015,60017,20017,70015,90014,30012,90011,60010,4009,40015,500Halaven (cancer)35,50026,60014,00010,7008,5006,9005,7004,7004,1003,500Japan7,9006,9004,0003,6003,2002,9002,6002,3002,1001,900US12,4007,5003,0001,500800400200100100100EU11,7008,7003,3002,6002,1001,7001,4001,100900700East Asia Global South3,5003,5003,7003,0002,4001,9001,5001,2001,000800Fycopma (epilepsy)25,90029,70032,00023,70017,70013,50010,5008,9007,8007,10031,500Japan6,9007,7008,9006,2004,3003,0002,1001,5001,1008009,000US800EU12,80015,70015,50010,9007,6005,3003,7002,6001,8001,30015,500Asia/Latin America1,9002,1002,1002,2002,3002,4002,5002,6002,7002,8002,000Aricept (Alzheimer&#x27;s disease)25,40025,10024,5008,9008,9008,9008,9008,0008,9008,9008,900Japan3,100East Asia Global South6,9007,7008,9008,9008,9008,9008,0008,9008,9008,9008,800rabeprazole (peptic ulcer)12,2004,2004,2004,2004,2004,4004,2004,2004,2004,000Japan: Pariet4,000US: AcipHexEast Asia Global South8,200Others in JapanMethycobal (nerve disorder)9,5008,6008,6008,4008,2008,0007,8007,6007,4007,3008,600Humira (rheumatoid arthritis)13,400Lunesta (sleep disorder)Lylica Co-promotion feePipeline contribution5002,5006,30013,50023,50033,60043,300OTC drugs22,70022,50023,00023,00023,00023,00023,20023,00023,20023,00023,000Others, net133,900156,700168,100-------",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "775382a4cf826f45",
      "text": "Source: Company. Estimates by BoFA Global Research. Underlined products are off-patented.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c8c09ac90b4060ce",
      "text": "Exhibit 6: Contribution from new drug pipeline (New Chemical Entities) Focus on development of anti-cancer drug MORAb-202 and anti-Tau mAb E2814",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "fc36cb29fe388f7b",
      "text": "JPY in millionsCodeFY3/24FY3/25FY3/26eFY3/27eFY3/28eFY3/29eFY3/30eFY3/31eFY3/32eFY3/33eFY3/34ePipeline sales1,3506,10018,20052,300110,300171,400221,000269,600Risk adjusted6002,7006,70016,40031,30046,80060,10072,200US5002,5006,30013,50023,50033,60043,30050,800Europe and Canada1,3004,5007,8009,30011,900Japan1005001,2003,0005,4008,20010,90013,100Emerging countries2006001,2001,8002,4002,8003,1003,300NeurologyStageProb.lorcaserin/E2023 (Dravet syndrome)1,0005,00010,00018,00027,00035,10042,10046,300Risk adjustedP350%5002,5005,0009,00013,50017,60021,10023,200E2027 (DLB)6,00012,00018,00023,40028,100Risk adjustedP220%1,2002,4003,6004,7005,600E2814 (Alzheimer&#x27;s disease)2,0008,50019,50035,10052,70068,500Risk adjustedP2/330%6002,6005,90010,50015,80020,600OncologyMORAb-202 (Ovarian cancer, etc)3,00012,50028,50048,00066,60083,100Risk adjustedP220%6002,5005,7009,60013,30016,600E7386 (Solid tumor)1,0004,0009,00015,00020,70025,800Risk adjustedP1/210%1004009001,5002,1002,600tasugratinib/E7090 (Cholangiocarcinoma)3501,1002,2003,3004,3005,2005,7006,000Risk adjustedP220%1002004007009001,0001,100Otherdotinurat/FYU-981 (Gout, Hyperuricemia)4001,2002,4003,6004,7005,6006,2006,5006,500Risk adjustedP250%2006001,2001,8002,4002,8003,1003,3003,300E6742/SLE1,2003,6007,20010,80014,00016,80018,500Risk adjustedP1/220%2007001,4002,2002,8003,4003,700",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "24a561aa54eacb2d",
      "text": "Note: e BofA Global Research estimates. This chart does not include line extension projects (additional indication and formulation, etc). We have included the expected contribution from these into the sales estimate of existing products.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "413355db16a5224a",
      "text": "BofA GLOBAL RESEARCH",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "d7204256953425ca",
      "text": "We base our \\(\\) 3,800\\(price objective on our DCF model, while also taking into account valuations such as P/E and P/B. Our DCF assumptions are risk - free rate 1.5%, equity risk premium 5.5%, terminal growth 1% and tax rate 40%. Individual company FCF risk is reflected in the stock beta, which takes into account quantitative risk based on new drug development scenario analysis and qualitative risk based on factors such as management strategies, and it is set at a tiered level within the sector. The stock's two- year adjusted beta is 0.89, and we base our price objective on a stock beta of 1.06 and WACC of 6.6%. Our PO corresponds to a P/E of 20x or FY3/27 EPS forecast. Downside risks are (1) mainstay drugs missing company guidance, (2) cancellation or postponement of new product development or changes in product evaluation, (3) adverse decisions by regulatory authorities in other countries and harsh stances on coverage by public health insurance, and (4) divergence between actual conditions and those assumed in our DCF calculations. Upside risks are greater- than- expected sales of Leqembi and development successes that generate data differentiating new drug candidates.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "76407af4104ec0db",
      "text": "APR-Healthcare Coverage Cluster",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "d12564b10f8fbe89",
      "text": "Investment ratingCompanyBofA TickerBloomberg symbolAnalystIHH Healthcare BhdXFAHFIHH SPNeha ManpuriaImeikZMITF300896 CHEthan CuiInnoventIVBXF1801 HKDavid LiIntegral DiagnosticsITGDFIDX AULyanne HarrisonJinxin FertilityJXFG1951 HKEthan CuiJinyu Bio-TechXMTDF600201 CHDavid LiJMDCJMDCF4483 JPRitsuo WatanabeKyowa KirinKYKOF4151 JPKoichi MameganoMedleyXEQNF4480 JPRitsuo WatanabeMindrayXDWF300760 CHSandra SunNxera PharmaSOLTF4565 JPKoichi MameganoOtsuka HDOTSKF4578 JPKoichi MameganoOtsuka HDOTSKYOTSKY USKoichi MameganoPharmaronPHBBF3759 HKDavid LiPolynovoCALZFPNV AULyanne HarrisonPram 9 HospitalXPNHFPR9 TBTeerapol Udomevj, CFAResMed IncRSMDFRMD AULyanne HarrisonResMed Inc.RMDRMD USLyanne HarrisonSanten Pharm.SNPHF4536 JPKoichi MameganoSawai Group HoldingsSWGHF4887 JPRitsuo WatanabeShanghai PharmaceuticalsSHPMF2607 HKDavid LiShanghai United ImagingXCAOF688271 CHSandra SunSHIMADZUSHMZF7701 JPRitsuo WatanabeShionogiSGIQF4507 JPKoichi MameganoShionogiSGIQYSGIQY USKoichi MameganoSino BiopharmSBMFF1177 HKDavid LiSinopharmSHTDF1099 HKDavid LiSonic Healthcare LimitedSKHCFSHL AULyanne HarrisonSysmexSSMXF6869 JPRitsuo WatanabeTakeda Pharm.TKPHF4502 JPKoichi MameganoTakeda Pharm.TAKTAK USKoichi MameganoTerumoTRUMF4543 JPRitsuo WatanabeTigerMedHTMDF3347 HKDavid LiWuxi ApptecWUXIF2359 HKDavid LiWuxi ApptecXLUHF603259 CHDavid LiYunnan BaiyaoYBAIF000538 CHSandra SunZhifeiXCHOF300122 CHDavid LiNEUTRALAlkemXAMLFALKEM INNeha ManpuriaAsahi IntecAHICF7747 JPRitsuo WatanabeAstellas PharmaALPMF4503 JPKoichi MameganoAstellas PharmaALPMYALPMY USKoichi MameganoBangkok Dusit Medical ServicesBDMSFBDMS TBTeerapol Udomevj, CFAChugai Pharm.CHGCF4519 JPKoichi MameganoCochlear LimitedCHEOFCOH AULyanne HarrisonEBOS Group LimitedEBOSFEBO NZLyanne HarrisonEBOS Group LimitedXEBOFEBO AULyanne HarrisonEverest MedicineXMLKF1952 HKDavid LiFisher &amp;amp; Paykel HealthcareXPAXFFPH AULyanne HarrisonFisher &amp;amp; Paykel HealthcareFSPKFFPH NZLyanne HarrisonFujifilm HoldingsFUJIF4901 JPRitsuo WatanabeFUJIFILM HoldingsFUJIFFUJIF USRitsuo WatanabeKelun-BiotechXSKBF6990 HKDavid LiLupinXEFSFLPC INNeha ManpuriaM3MTHRF2413 JPRitsuo WatanabeMax HealthcareXMHIFMAXHEALT INNeha ManpuriaNew Industries Biomedical EngineeringXSNQF300832 CHSandra SunOlympus Corp.OCPNF7733 JPRitsuo WatanabeRamsay Health Care LimitedRMSYFRHC AULyanne HarrisonTopchoice MedicalXZDXF600763 CHEthan CuiTorrent PharmaTOPHFTRP INNeha ManpuriaWuXi BiologicsWXIBF2269 HKDavid LiZai LabZLABZLAB USDavid LiZai LabXCDZF9688 HKDavid LiZydus LifesciencesXMQLFZYDUSLIF INNeha Manpuria",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "692edded0d86df19",
      "text": "Investment ratingCompanyBofA TickerBloomberg symbolAnalystUNDERPERFORMAin HoldingsAINPF9627 JPRitsuo WatanabeAsymchem LaboratoriesXALPF002821 CHDavid LiAutobio Diagnostics Co LtdXQDXF603658 CHSandra SunBaiyunshanXOUFF600332 CHSandra SunBeijing Wantai Biological PharmacyXBHIIF603392 CHDavid LiCiplaXCLAFCIPLA INNeha ManpuriaCSPC PharmaceuticalCHJTF1093 HKEthan CuiEisaiESALF4523 JPKoichi MameganoFrontageFGHQF1521 HKDavid LiHelaius LimitedPHCRFHLS AULyanne HarrisonHengrui MedicineXMOKF600276 CHDavid LiJoinn LabXQTSF6127 HKDavid LiJoinn LabJOLCF603127 CHDavid LiMankind PharmaXDXZFMANKIND INNeha ManpuriaMedipal HoldingsMEPDF7459 JPRitsuo WatanabeOno Pharm.OPHLF4528 JPKoichi MameganoOvctekXOCKF300595 CHDavid LiPharmaronXLYGF300759 CHDavid LiPHC HoldingsPHCCF6523 JPRitsuo WatanabePien Tze HuangXUVHF600436 CHSandra SunShanghai PharmaceuticalsXKCRF601607 CHDavid LiSMSSMSZF2175 JPRitsuo WatanabeSun PharmaXPUCFSUNP INNeha ManpuriaTigerMedXHTHF300347 CHDavid LiYifeng PharmacyXYHCF603939 CHEthan CuiRSTRMicroPortMCRPF853 HKSandra SunTRYTXHXTF9164 JPRitsuo Watanabe",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "56d6c05740162cd2",
      "text": "Return On Capital Employed",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "e59427b034d7c0f0",
      "text": "Return On Equity Operating Margin Earnings Growth Free Cash Flow",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "aac0cccdfb778794",
      "text": "Cash Realization Ratio",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "19f0f2c9a7adbe63",
      "text": "Asset Replacement Ratio",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "aa8ad21fa911b43e",
      "text": "Net Debt-To-Equity Ratio",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "59bd06b2e70a378d",
      "text": "Price / Earnings Ratio",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "f7651b3d1ce321f2",
      "text": "Free Cash Flow Yield",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "3c12ff78271f9349",
      "text": "Enterprise Value/Sales",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "49ae56b82a72045f",
      "text": "NOPAT=(EBIT+InterestIncome) x(1-Tax Rate)+Goodwill Amortization",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "f010191e78cec8a7",
      "text": "Expected 5 Year CAGR From Latest Actual",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "05d3f95f525af15a",
      "text": "Cash Flow From Operations - Total Capex",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5a94ead9a9773ec2",
      "text": "Cash Flow From Operations",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "6729f099cfb8915b",
      "text": "Net Debt = Total Debt-Cash & Equivalents",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "3bb25faf4832a4bb",
      "text": "Annualised Declared Cash Dividend",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "27b04453db2d3be0",
      "text": "Cash Flow From Operations - Total Capex",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "fc7b7b04374502bc",
      "text": "EV = Current Share Price x Current Shares + Minority Equity + Net Debt +",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "81c7d6bb9d05ebf5",
      "text": "Other LT Liabilities",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "f0d4b5a08d585ec7",
      "text": "Total Assets-Current Liabilities +ST Debt +Accumulated Goodwill",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "0975788ba5ce52f4",
      "text": "Shareholders' Equity",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "fd7899b8827005d2",
      "text": "Diluted Earnings Per Share (Basis As Specified)",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "8da6d3a5b6b1f59f",
      "text": "Shareholders' Equity / Current Basic Shares",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "61eb2b19bca70c4c",
      "text": "Market Cap = Current Share Price x Current Basic Shares",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "63ad9f60aae7eb3f",
      "text": "Basic EBIT + Depreciation + Amortization",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "a52d54aca54394f7",
      "text": "Methodisthe set of BofA Global Research standard measures that serve to maintain global consistency under three broad headings: Business Performance, Quality of Earnings, and validations. The key features of",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "c0fd2e41eae3eaf5",
      "text": "Method are: A consistently structured, detailed, and transparent methodology. Guidelines to maximize the effectiveness of the comparative valuation process, and to identify some common pitfalls.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "301c2fb810b3c012",
      "text": "Databoss is our real-time global research database that is sourced directly from our equity analysts' earnings models and includes forecasted as well as historical data for income statements, balance sheets, and cash flow statements for companies covered by BofA Global Research.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "77e55f3bcd0fe9a3",
      "text": "Profile, Qmethod are service marks of Bank of America Corporation. Databoss is a registered service mark of Bank of America Corporation.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "c48cac67942298c9",
      "text": "p t sources including BofA Securities trading desks.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "7b40ad339cd0f076",
      "text": "The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "985accfcb8658695",
      "text": "e with any investment decision, or for a necessary explanation of its contents.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "fffeb77dd79018f9",
      "text": "Offices of BofA or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "97a775b6ae5cedfb",
      "text": "Refer to BofA Global Research policies relating to conflicts of interest.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "8324923f8912ec09",
      "text": "BofA Securities includes BofA Securities, Inc. (BofAS) and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. BofA Securities is a global brand for BofA Global Research.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "f734e19d4df5beea",
      "text": "Information relating to Non- US affiliates of BofA Securities and Distribution of Affiliate Research Reports:",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "82925b94650b59ef",
      "text": "BofA and/or Merrill Lynch, Pierce, Fenner & Smith Incorporated (\"MLPF&s\") may in the future distribute, information of the following non- US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by the Financial Sector Conduct Authority; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers (AMF). BofA Securities Europe SA (\"BofASE\") with registered address at 51, rue La Boétie, 75008 Paris is registered under no 842 602 690 RCS Paris. In accordance with the provisions of French Code Monétaire et Financier (Monetary and Financial Code), BofASE is an établissement de crédit et d'investissement (credit and investment institution) that is authorised and supervised by the European Central Bank and the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers. BofASE's share capital can be found at www.bofaml.com/BofAS Disclaimer: BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI); BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company, Frankfurt Branch regulated by BaFin, the ECB and the CBI; BofA Europe (Madrid): Bank of America Europe Designated Activity Company, Sucursal en España, regulated by the Bank of Spain, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch Equities (Australia) Limited, regulated by the Australian Securities and Investments Commission; Merrill Lynch (Hong Kong): Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSFC); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Canadian Investment Regulatory Organization; Merrill Lynch (Mexico): Merrill Lynch Mexico, SA de CV, Casa de Bolsa, regulated by the Comisión Nacional Bancaria y de Valores; BofAS Japan: BofA Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India: BofA Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Israel): Merrill Lynch Israel Limited, regulated by Israel Securities Authority; Merrill Lynch (DIFC): Merrill Lynch International (DIFC Branch), regulated by the Dubai Financial Services Authority (DFSA); Merrill Lynch (Brazil): Merrill Lynch S.A. Corretora de Titulos e Valores Mobiliarios, regulated by Comissão de Valores Mobiliarios; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority. This information: has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSFC; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India by BofAS India; and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to Wholesale clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information prepared and issued by Merrill Lynch (DIFC) is done so in accordance with the requirements of the DFSA conduct of business rules. BofA Europe (Frankfurt) distributes this information in Germany and is regulated by BaFin, the ECB and the CBI. BofA Securities entities, including BofA Europe and BofASE (France), may outsource/delete the marketing and/or provision of certain research services or aspects of research services to other branches or members of the BofAS Securities group. You may be contacted by a different BofAS Securities entity acting for and on behalf of your service provider where permitted by applicable law. This does not change your service provider. Please refer to the Electronic Communications Disclaimers for further information.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "89582b8d959c5c4b",
      "text": "This information has been prepared and issued by BofAS and/or one or more of its non- US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&s is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&s clients in the US by its non- US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&s and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information. For clients that are not accredited investors, expert investors or institutional investors Merrill Lynch (Singapore) Pte Ltd accepts full responsibility for the contents of this information distributed to such clients in Singapore.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "383eac3d1d701fa3",
      "text": "General Investment Related Disclosures:",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "969ce5e70bcdffb3",
      "text": "Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofAS Securities. This document provides general information only, and has been prepared for, and is intended for general distribution to, BofAS Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g. options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific persons(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "634dbc55ce5be7e0",
      "text": "Securities and other financial instruments referred to herein, or recommended, offered or sold by BofAS Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. Digital assets are extremely speculative, volatile and are largely unregulated. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "b5d12c44bfdae5a6",
      "text": "This report may contain a short- term trading idea or recommendation, which highlights a specific near- term catalyst or event impacting the issuer or the market that is anticipated to have a short- term price impact on the equity securities of the issuer. Short- term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short- term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "f74d4a9ec715f2ea",
      "text": "BofAS Securities is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to \"short\" securities or other financial instruments and that such",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "4cbdf25fc25b25dd",
      "text": "action may be limited by regulations prohibiting or restricting \"shortselling\" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "1dda6831b5ffa173",
      "text": "Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned herein. Investors in such securities and instruments, including ADRs, effectively assume currency risk.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "6d540c580b7328fb",
      "text": "BofA or of its affliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofAS or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "1fa3c21d17967c15",
      "text": "BofA Securitie, through busines units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information. In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofAS). If such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "db47638ef088896b",
      "text": "Copyright 2025 Bank of America Corporation. All rights reserved. iQdatabase is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, in any form or manner, without the express written consent of BofA Securities. This document and its content is provided solely for informational purposes and cannot be used for training or developing artificial intelligence (AI) models or as an input in any AI application (collectively, an AI tool). Any attempt to utilize this document or any of its content in connection with an AI tool without explicit written permission from BofA Global Research is strictly prohibited. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly- available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities. Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co- defendants or co- plaintiffs with or involving issuers mentioned in this material is based on public information. Facts and views presented in this material that relate to any such proceedings have not been reviewed by, discussed with, and may not reflect information known to, professionals in other business areas of BofA Securities in connection with the legal proceedings or matters relevant to such proceedings.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "5af587d6182e7f9f",
      "text": "This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "3efc452afa1a1aa4",
      "text": "Any information relating to sustainability in this material is limited as discussed herein and is not intended to provide a comprehensive view on any sustainability claim with respect to any issuer or security.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "1faac5dcdb3b08de",
      "text": "Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "58a8b283c9100452",
      "text": "The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third- party websites. BofA Securities is not responsible for the content of any third- party website or any linked content contained in a third- party website. Content contained on such third- party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third- party website is at your own risk, and you should always review the terms and privacy policies at third- party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "56056481d97dc6fb",
      "text": "All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "735f5b1909f31e83",
      "text": "Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Securities policy- related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "2192916bbf1eba5b",
      "text": "Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "d7ebccf250e18d45",
      "text": "In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies. Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.",
      "page": 12,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "e1e651d2efa1d5cc",
      "name": "AFS License",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "101d9e0274c5aa25",
      "name": "Accumulated Goodwill",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "bc8f3c5f919cb82e",
      "name": "Actual\n\nCash",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e195d3a47b7917a1",
      "name": "Affiliate Research",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "645f128997f142a3",
      "name": "Ain Holdings",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0932cb8d2b0b0ac7",
      "name": "America Corporation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b0c2f9a72e612607",
      "name": "America Europe",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "bef26f2f1d105ee8",
      "name": "Amortization\n\nMethodisthe",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0f7f79040b6157d2",
      "name": "Amortization\n\nShareholders",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "517917b86efb07cf",
      "name": "Analyst Certification",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "84ff7b3b3263e4ff",
      "name": "Any US",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cb358c677450e407",
      "name": "Asahi Intec",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2ebc1f6a39f03ec8",
      "name": "Asia Pacific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "687cd03d96e468d6",
      "name": "Asset Replacement",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "88e7c22574311b3f",
      "name": "Astellas Pharma",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d7ca112168434181",
      "name": "Asymchem Laboratories",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "98e6ff96d07c787b",
      "name": "Australia Branch",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d16f4c8368da6dbe",
      "name": "Australian Prudential",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "bc98bb53ad7f2a24",
      "name": "Australian Securities",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2cf9ed01d5cfe61e",
      "name": "Authorised Deposit",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "c17332547eb53229",
        "value": -0.235,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>213.71</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>EPS Change (YoY)</td><td>-23.5%</td><td>9.5%</td><td>2.0%</td><td>15.2%</td><td>12.3%</td><td></td><td></td><td></td><td></td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2c7cb8eb90ece62d",
        "value": 0.095,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td></td><td></td><td></td><td></td><td></td></tr><tr><td>EPS Change (YoY)</td><td>-23.5%</td><td>9.5%</td><td>2.0%</td><td>15.2%</td><td>12.3%</td><td></td><td></td><td></td><td></td><td></td></tr>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "bdcda6afa47f5fc9",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td><td></td><td></td></tr><tr><td>EPS Change (YoY)</td><td>-23.5%</td><td>9.5%</td><td>2.0%</td><td>15.2%</td><td>12.3%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Conse",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ee52548143380d66",
        "value": 0.152,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td></tr><tr><td>EPS Change (YoY)</td><td>-23.5%</td><td>9.5%</td><td>2.0%</td><td>15.2%</td><td>12.3%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Consensus EPS (Vis",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a34db7fb125f390e",
        "value": 0.12300000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td></tr><tr><td>EPS Change (YoY)</td><td>-23.5%</td><td>9.5%</td><td>2.0%</td><td>15.2%</td><td>12.3%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Consensus EPS (Visible Alpha)</t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2cf8da2380604e8c",
        "value": 0.035,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>21.5x</td><td></td><td></td><td></td><td></td></tr><tr><td>Dividend Yield*</td><td></td><td>3.5%</td><td>3.5%</td><td>3.5%</td><td>3.5%</td><td></td><td></td><td></td><td></td><td></td></tr><t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2be678e90801cdcd",
        "value": 0.035,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td><td></td><td></td><td></td></tr><tr><td>Dividend Yield*</td><td></td><td>3.5%</td><td>3.5%</td><td>3.5%</td><td>3.5%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P/B</td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5ec169d38f417ed1",
        "value": 0.035,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td><td></td><td></td></tr><tr><td>Dividend Yield*</td><td></td><td>3.5%</td><td>3.5%</td><td>3.5%</td><td>3.5%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P/B</td><td></td><td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9d002377cce8bae5",
        "value": 0.035,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td><td></td></tr><tr><td>Dividend Yield*</td><td></td><td>3.5%</td><td>3.5%</td><td>3.5%</td><td>3.5%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P/B</td><td></td><td>1.5x</td><td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5438f0753e73215e",
        "value": 0.024,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>11.2x</td><td></td><td></td><td></td><td></td></tr><tr><td>Free Cash Flow Yield*</td><td></td><td>2.4%</td><td>0.5%</td><td>2.4%</td><td>1.4%</td><td>0.3%</td><td></td><td></td><td></td><td></td></t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a2c11a26fbfe9c68",
        "value": 0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td></td><td></td><td></td></tr><tr><td>Free Cash Flow Yield*</td><td></td><td>2.4%</td><td>0.5%</td><td>2.4%</td><td>1.4%</td><td>0.3%</td><td></td><td></td><td></td><td></td></tr></table> \\\\",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "cdaeaf95ea863e35",
        "value": 0.024,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td></td><td></td></tr><tr><td>Free Cash Flow Yield*</td><td></td><td>2.4%</td><td>0.5%</td><td>2.4%</td><td>1.4%</td><td>0.3%</td><td></td><td></td><td></td><td></td></tr></table> \\\\* For full de",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "194647552d604797",
        "value": 0.013999999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td></td></tr><tr><td>Free Cash Flow Yield*</td><td></td><td>2.4%</td><td>0.5%</td><td>2.4%</td><td>1.4%</td><td>0.3%</td><td></td><td></td><td></td><td></td></tr></table> \\\\* For full definitions of ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b75597d3bce3a0e7",
        "value": 0.003,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Free Cash Flow Yield*</td><td></td><td>2.4%</td><td>0.5%</td><td>2.4%</td><td>1.4%</td><td>0.3%</td><td></td><td></td><td></td><td></td></tr></table> \\\\* For full definitions of \\(\\sqrt{\\math",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "631d748b2f27d392",
        "value": 0.9109999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6.7</td></tr><tr><td>Average Daily Value (Smn)</td><td>44.2 USD</td></tr><tr><td>Free Float</td><td>91.1%</td></tr><tr><td>BofA Ticker / Exchange</td><td>ESALF / TYO</td></tr><tr><td>Bloomberg / Reute",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1b5b435024a805a0",
        "value": 0.055999999999999994,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>Bloomberg / Reuters</td><td>4523 JP / 4523.T</td></tr><tr><td>ROE (2026E)</td><td>5.6%</td></tr><tr><td>Net Dbt to Eqty (Mar-2025A)</td><td>-13.4%</td></tr></table> BBM: Blood- based",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9ce91f9c60ecb518",
        "value": -0.134,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "23.T</td></tr><tr><td>ROE (2026E)</td><td>5.6%</td></tr><tr><td>Net Dbt to Eqty (Mar-2025A)</td><td>-13.4%</td></tr></table> BBM: Blood- based biomarker SC- Al: Subcutaneous formulation with Auto- Inj",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e0b4485bc79b2605",
        "value": 3800.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "ed profit growth Reiterate Rating: UNDERPERFORM | PO: 3,800 JPY | Price: 4,597 JPY ## Raise PO to ¥3,800; reiterate Underperform 1Q results confirmed sales growth for Leqembi (Alzheimer's disease ther",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "dcc866f52175aae0",
        "value": 3330.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "d operating profit (OP) estimates by \\(15\\%\\) . Consequently, we lift our price objective (PO) from ¥3,330 to ¥3,800, based on discounted cash flow (DCF). We estimate that earnings will bottom out, bu",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "dfaaa4d887639fee",
        "value": 3800.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "g profit (OP) estimates by \\(15\\%\\) . Consequently, we lift our price objective (PO) from ¥3,330 to ¥3,800, based on discounted cash flow (DCF). We estimate that earnings will bottom out, but sustaine",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "3b29a68de204d1c9",
        "value": -0.004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1</td><td>789,400</td><td>797,500</td><td>828,000</td><td>890,500</td></tr><tr><td>% Change</td><td>-0.4%</td><td>6.4%</td><td>1.0%</td><td>3.8%</td><td>7.5%</td></tr><tr><td>Gross Profit</td><td>586,",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "a9ecf44848311fea",
        "value": 0.064,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "400</td><td>797,500</td><td>828,000</td><td>890,500</td></tr><tr><td>% Change</td><td>-0.4%</td><td>6.4%</td><td>1.0%</td><td>3.8%</td><td>7.5%</td></tr><tr><td>Gross Profit</td><td>586,417</td><td>62",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "3926cd3be191f03b",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "97,500</td><td>828,000</td><td>890,500</td></tr><tr><td>% Change</td><td>-0.4%</td><td>6.4%</td><td>1.0%</td><td>3.8%</td><td>7.5%</td></tr><tr><td>Gross Profit</td><td>586,417</td><td>620,593</td><td",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "bbb2d815ae8da549",
        "value": 0.038,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>828,000</td><td>890,500</td></tr><tr><td>% Change</td><td>-0.4%</td><td>6.4%</td><td>1.0%</td><td>3.8%</td><td>7.5%</td></tr><tr><td>Gross Profit</td><td>586,417</td><td>620,593</td><td>618,500</td>",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "47739c989f57f76e",
        "value": 0.075,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>890,500</td></tr><tr><td>% Change</td><td>-0.4%</td><td>6.4%</td><td>1.0%</td><td>3.8%</td><td>7.5%</td></tr><tr><td>Gross Profit</td><td>586,417</td><td>620,593</td><td>618,500</td><td>621,700</",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "d662dbf308c03128",
        "value": 0.33399999999999996,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3,408</td><td>54,378</td><td>59,800</td><td>63,700</td><td>72,100</td></tr><tr><td>% Change</td><td>33.4%</td><td>1.8%</td><td>10.0%</td><td>6.5%</td><td>13.2%</td></tr><tr><td>Net Interest &amp;amp; ",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "a764c349dcc70c8d",
        "value": 0.018000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "54,378</td><td>59,800</td><td>63,700</td><td>72,100</td></tr><tr><td>% Change</td><td>33.4%</td><td>1.8%</td><td>10.0%</td><td>6.5%</td><td>13.2%</td></tr><tr><td>Net Interest &amp;amp; Other Income</",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "b2574e46d089f634",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>59,800</td><td>63,700</td><td>72,100</td></tr><tr><td>% Change</td><td>33.4%</td><td>1.8%</td><td>10.0%</td><td>6.5%</td><td>13.2%</td></tr><tr><td>Net Interest &amp;amp; Other Income</td><td>8,416<",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "ccce15133ac597d0",
        "value": 0.065,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>63,700</td><td>72,100</td></tr><tr><td>% Change</td><td>33.4%</td><td>1.8%</td><td>10.0%</td><td>6.5%</td><td>13.2%</td></tr><tr><td>Net Interest &amp;amp; Other Income</td><td>8,416</td><td>6,688<",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "b876faa0b5153d43",
        "value": 0.132,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>72,100</td></tr><tr><td>% Change</td><td>33.4%</td><td>1.8%</td><td>10.0%</td><td>6.5%</td><td>13.2%</td></tr><tr><td>Net Interest &amp;amp; Other Income</td><td>8,416</td><td>6,688</td><td>6,700",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "692a76d16e10afbd",
        "value": 0.373,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1,823</td><td>61,065</td><td>66,500</td><td>70,300</td><td>78,600</td></tr><tr><td>% Change</td><td>37.3%</td><td>-1.2%</td><td>8.9%</td><td>5.7%</td><td>11.8%</td></tr><tr><td>Net Income</td><td>42,4",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "ba0c94b020a3bea0",
        "value": -0.012,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "61,065</td><td>66,500</td><td>70,300</td><td>78,600</td></tr><tr><td>% Change</td><td>37.3%</td><td>-1.2%</td><td>8.9%</td><td>5.7%</td><td>11.8%</td></tr><tr><td>Net Income</td><td>42,406</td><td>46,",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "343771ad88538f46",
        "value": 0.08900000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">66,500</td><td>70,300</td><td>78,600</td></tr><tr><td>% Change</td><td>37.3%</td><td>-1.2%</td><td>8.9%</td><td>5.7%</td><td>11.8%</td></tr><tr><td>Net Income</td><td>42,406</td><td>46,432</td><td>47",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "a38120a6ff09ab65",
        "value": 0.057,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>70,300</td><td>78,600</td></tr><tr><td>% Change</td><td>37.3%</td><td>-1.2%</td><td>8.9%</td><td>5.7%</td><td>11.8%</td></tr><tr><td>Net Income</td><td>42,406</td><td>46,432</td><td>47,374</td><td>",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "379f741d589ed0ca",
        "value": 0.11800000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>78,600</td></tr><tr><td>% Change</td><td>37.3%</td><td>-1.2%</td><td>8.9%</td><td>5.7%</td><td>11.8%</td></tr><tr><td>Net Income</td><td>42,406</td><td>46,432</td><td>47,374</td><td>54,574</td><t",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "f6112ea45fa3117d",
        "value": 0.043,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e*</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Return On Capital Employed</td><td>4.3%</td><td>4.7%</td><td>5.0%</td><td>5.7%</td><td>6.3%</td></tr><tr><td>Return On Equity</td><td>5",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "75091aca9ede07ac",
        "value": 0.047,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td></td><td></td></tr><tr><td>Return On Capital Employed</td><td>4.3%</td><td>4.7%</td><td>5.0%</td><td>5.7%</td><td>6.3%</td></tr><tr><td>Return On Equity</td><td>5.1%</td><td>5",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "886d5e810294ff84",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td></td><td></td></tr><tr><td>Return On Capital Employed</td><td>4.3%</td><td>4.7%</td><td>5.0%</td><td>5.7%</td><td>6.3%</td></tr><tr><td>Return On Equity</td><td>5.1%</td><td>5.4%</td><td>5",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "4e7f97cebd784f2c",
        "value": 0.057,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td></td></tr><tr><td>Return On Capital Employed</td><td>4.3%</td><td>4.7%</td><td>5.0%</td><td>5.7%</td><td>6.3%</td></tr><tr><td>Return On Equity</td><td>5.1%</td><td>5.4%</td><td>5.6%</td><td>6",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "15c64b99c6d3ae00",
        "value": 0.063,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>Return On Capital Employed</td><td>4.3%</td><td>4.7%</td><td>5.0%</td><td>5.7%</td><td>6.3%</td></tr><tr><td>Return On Equity</td><td>5.1%</td><td>5.4%</td><td>5.6%</td><td>6.4%</td><td>7",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "110a2695c3759f21",
        "value": 0.051,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">4.3%</td><td>4.7%</td><td>5.0%</td><td>5.7%</td><td>6.3%</td></tr><tr><td>Return On Equity</td><td>5.1%</td><td>5.4%</td><td>5.6%</td><td>6.4%</td><td>7.1%</td></tr><tr><td>Operating Margin</td><td>7",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "8ba7cb2f68190646",
        "value": 0.054000000000000006,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">4.7%</td><td>5.0%</td><td>5.7%</td><td>6.3%</td></tr><tr><td>Return On Equity</td><td>5.1%</td><td>5.4%</td><td>5.6%</td><td>6.4%</td><td>7.1%</td></tr><tr><td>Operating Margin</td><td>7.2%</td><td>6",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "4977950bd6980d41",
        "value": 0.055999999999999994,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">5.0%</td><td>5.7%</td><td>6.3%</td></tr><tr><td>Return On Equity</td><td>5.1%</td><td>5.4%</td><td>5.6%</td><td>6.4%</td><td>7.1%</td></tr><tr><td>Operating Margin</td><td>7.2%</td><td>6.9%</td><td>7",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "1ec22864ab0d4aa8",
        "value": 0.064,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">5.7%</td><td>6.3%</td></tr><tr><td>Return On Equity</td><td>5.1%</td><td>5.4%</td><td>5.6%</td><td>6.4%</td><td>7.1%</td></tr><tr><td>Operating Margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "83571c729de1a834",
        "value": 0.071,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">6.3%</td></tr><tr><td>Return On Equity</td><td>5.1%</td><td>5.4%</td><td>5.6%</td><td>6.4%</td><td>7.1%</td></tr><tr><td>Operating Margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "e50bc076c544d9e3",
        "value": 0.07200000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">5.1%</td><td>5.4%</td><td>5.6%</td><td>6.4%</td><td>7.1%</td></tr><tr><td>Operating Margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td></tr><tr><td>iQ method™ - Quality of Ea",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "5711710ffe569358",
        "value": 0.069,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">5.4%</td><td>5.6%</td><td>6.4%</td><td>7.1%</td></tr><tr><td>Operating Margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td></tr><tr><td>iQ method™ - Quality of Earnings*</td><",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "8bf5d7ae950b8847",
        "value": 0.075,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">5.6%</td><td>6.4%</td><td>7.1%</td></tr><tr><td>Operating Margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td></tr><tr><td>iQ method™ - Quality of Earnings*</td><td></td><td><",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "ef99d7d4ccfbaf79",
        "value": 0.077,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">6.4%</td><td>7.1%</td></tr><tr><td>Operating Margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td></tr><tr><td>iQ method™ - Quality of Earnings*</td><td></td><td></td><td></td>",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "2c533f8d43ee8235",
        "value": 0.081,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">7.1%</td></tr><tr><td>Operating Margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td></tr><tr><td>iQ method™ - Quality of Earnings*</td><td></td><td></td><td></td><td></td><td>",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "8e833ebf48cb9e8e",
        "value": 0.292,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">1.0x</td><td>0.9x</td><td>1.0x</td><td>1.1x</td></tr><tr><td>Tax Rate (Reported)</td><td>-</td><td>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-<",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "0c59702e666885dc",
        "value": 0.213,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0.9x</td><td>1.0x</td><td>1.1x</td></tr><tr><td>Tax Rate (Reported)</td><td>-</td><td>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-</td><td>-10.9%",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "03cce7379184c83b",
        "value": 0.263,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".0x</td><td>1.1x</td></tr><tr><td>Tax Rate (Reported)</td><td>-</td><td>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-</td><td>-10.9%</td><td>-13.4",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "51d3e43a535451bd",
        "value": 0.201,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1x</td></tr><tr><td>Tax Rate (Reported)</td><td>-</td><td>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-</td><td>-10.9%</td><td>-13.4%</td><td>-11.",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "5e761dc3f0e89ed5",
        "value": -0.109,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>21.3%</td><td>26.3%</td><td>20.1%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-</td><td>-10.9%</td><td>-13.4%</td><td>-11.8%</td><td>-8.6%</td></tr><tr><td>Interest Cover</td><td>-</td><td",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "835e42d3e5f5ba72",
        "value": -0.134,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>26.3%</td><td>20.1%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-</td><td>-10.9%</td><td>-13.4%</td><td>-11.8%</td><td>-8.6%</td></tr><tr><td>Interest Cover</td><td>-</td><td>22.4x</td><td>",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "a4bf3671ead064b3",
        "value": -0.11800000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>20.1%</td></tr><tr><td>Net Debt-to-Equity Ratio</td><td>-</td><td>-10.9%</td><td>-13.4%</td><td>-11.8%</td><td>-8.6%</td></tr><tr><td>Interest Cover</td><td>-</td><td>22.4x</td><td>15.5x</td><td>1",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "d821f34869cb8580",
        "value": -0.086,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>Net Debt-to-Equity Ratio</td><td>-</td><td>-10.9%</td><td>-13.4%</td><td>-11.8%</td><td>-8.6%</td></tr><tr><td>Interest Cover</td><td>-</td><td>22.4x</td><td>15.5x</td><td>17.1x</td><td>18",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "386a27587ee4d50c",
        "value": 0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td></tr><tr><td>WACC</td><td>FCF NPV (12Y)</td><td>PV of terminal FCF at perpetuity of 0.5%</td><td>1.0%</td><td>1.5%</td><td>Net Cash FY3/22</td><td>Present Value of Equity 0.5%</td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "3a6e8d5afd08274a",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>WACC</td><td>FCF NPV (12Y)</td><td>PV of terminal FCF at perpetuity of 0.5%</td><td>1.0%</td><td>1.5%</td><td>Net Cash FY3/22</td><td>Present Value of Equity 0.5%</td><td>1.0%</td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2d8b29a258ea3454",
        "value": 0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>WACC</td><td>FCF NPV (12Y)</td><td>PV of terminal FCF at perpetuity of 0.5%</td><td>1.0%</td><td>1.5%</td><td>Net Cash FY3/22</td><td>Present Value of Equity 0.5%</td><td>1.0%</td><td>1.5%</td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "184ec64245068c6b",
        "value": 0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "erpetuity of 0.5%</td><td>1.0%</td><td>1.5%</td><td>Net Cash FY3/22</td><td>Present Value of Equity 0.5%</td><td>1.0%</td><td>1.5%</td><td></td><td></td><td>Equity Value per Share: JPY 0.5%</td><td>1.",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2fbb420af99103e5",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0.5%</td><td>1.0%</td><td>1.5%</td><td>Net Cash FY3/22</td><td>Present Value of Equity 0.5%</td><td>1.0%</td><td>1.5%</td><td></td><td></td><td>Equity Value per Share: JPY 0.5%</td><td>1.5%</td></tr><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "f88aecf28510afb0",
        "value": 0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1.0%</td><td>1.5%</td><td>Net Cash FY3/22</td><td>Present Value of Equity 0.5%</td><td>1.0%</td><td>1.5%</td><td></td><td></td><td>Equity Value per Share: JPY 0.5%</td><td>1.5%</td></tr><tr><td>6.4%</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a336031752a631d4",
        "value": 0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "alue of Equity 0.5%</td><td>1.0%</td><td>1.5%</td><td></td><td></td><td>Equity Value per Share: JPY 0.5%</td><td>1.5%</td></tr><tr><td>6.4%</td><td>342,150</td><td>608,950</td><td>668,362</td><td>739,",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "30e291771f94da0d",
        "value": 0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "y 0.5%</td><td>1.0%</td><td>1.5%</td><td></td><td></td><td>Equity Value per Share: JPY 0.5%</td><td>1.5%</td></tr><tr><td>6.4%</td><td>342,150</td><td>608,950</td><td>668,362</td><td>739,832</td><td>1",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "3f1251172ff74d48",
        "value": 0.064,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>1.5%</td><td></td><td></td><td>Equity Value per Share: JPY 0.5%</td><td>1.5%</td></tr><tr><td>6.4%</td><td>342,150</td><td>608,950</td><td>668,362</td><td>739,832</td><td>134,662</td><td>1,085,7",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "536d7d4eebd49724",
        "value": 0.065,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">1,085,762</td><td>1,145,174</td><td>1,216,644</td><td></td><td></td><td></td><td></td></tr><tr><td>6.5%</td><td>339,816</td><td>592,413</td><td>649,219</td><td>717,326</td><td>134,662</td><td>1,066,8",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c0fe807559bddb4c",
        "value": 0.066,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>1,123,698</td><td>1,191,804</td><td></td><td></td><td>3,786</td><td>3,994</td></tr><tr><td>6.6%</td><td>337,504</td><td>576,490</td><td>630,838</td><td>695,786</td><td>134,662</td><td>1,048,6",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "e8dcd4e5fde5bb32",
        "value": 0.067,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>1,103,004</td><td>1,167,952</td><td></td><td></td><td>3,721</td><td>3,919</td></tr><tr><td>6.7%</td><td>335,212</td><td>561,150</td><td>613,177</td><td>675,157</td><td>134,662</td><td>1,031,0",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "8d628da33a5c37fc",
        "value": 0.068,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>1,083,052</td><td>1,145,032</td><td></td><td></td><td>3,657</td><td>3,846</td></tr><tr><td>6.8%</td><td>332,942</td><td>546,365</td><td>596,198</td><td>655,386</td><td>134,662</td><td>1,013,9",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "5008a04e28d58d40",
        "value": 0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Risk free rate</td><td>1.5%</td><td>Cost of Debt (rate and weight)</td><td></td><td></td><td></td><td>2.0%</td><td></td><td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "08509488822f9882",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "sk free rate</td><td>1.5%</td><td>Cost of Debt (rate and weight)</td><td></td><td></td><td></td><td>2.0%</td><td></td><td>14%</td><td></td><td></td><td></td><td></td></tr><tr><td>Market Risk Premium</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "51a5a948e2f28c6e",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".5%</td><td>Cost of Debt (rate and weight)</td><td></td><td></td><td></td><td>2.0%</td><td></td><td>14%</td><td></td><td></td><td></td><td></td></tr><tr><td>Market Risk Premium</td><td>5.5%</td><td>Co",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "9a37f96af307ece1",
        "value": 0.055,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td></td><td>14%</td><td></td><td></td><td></td><td></td></tr><tr><td>Market Risk Premium</td><td>5.5%</td><td>Cost of Equity (rate and weight)</td><td></td><td></td><td></td><td>7.4%</td><td></td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "9ab80332174c00d9",
        "value": 0.07400000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "sk Premium</td><td>5.5%</td><td>Cost of Equity (rate and weight)</td><td></td><td></td><td></td><td>7.4%</td><td></td><td>86%</td><td></td><td></td><td></td><td></td></tr></table> <table><tr><td></td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "0ba71b52045108e9",
        "value": 0.86,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>Cost of Equity (rate and weight)</td><td></td><td></td><td></td><td>7.4%</td><td></td><td>86%</td><td></td><td></td><td></td><td></td></tr></table> <table><tr><td></td><td colspan=\"3\">Quanti",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "cd6512d0c6b93976",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td></td><td></td><td></td></tr><tr><td rowspan=\"3\">Qualitative volatility</td><td>High</td><td>-10%</td><td>0%</td><td>10%</td><td>20%</td><td>30%</td><td>0.80</td><td>0.89</td><td>0.98</td></tr>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "35318921cf0c6d14",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td></td><td></td></tr><tr><td rowspan=\"3\">Qualitative volatility</td><td>High</td><td>-10%</td><td>0%</td><td>10%</td><td>20%</td><td>30%</td><td>0.80</td><td>0.89</td><td>0.98</td></tr><tr><td>Mediu",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "e3d4d73101f78925",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td></tr><tr><td rowspan=\"3\">Qualitative volatility</td><td>High</td><td>-10%</td><td>0%</td><td>10%</td><td>20%</td><td>30%</td><td>0.80</td><td>0.89</td><td>0.98</td></tr><tr><td>Medium</td><td>-",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "48c1092a3a0901b7",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td rowspan=\"3\">Qualitative volatility</td><td>High</td><td>-10%</td><td>0%</td><td>10%</td><td>20%</td><td>30%</td><td>0.80</td><td>0.89</td><td>0.98</td></tr><tr><td>Medium</td><td>-20%</td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "36649efcd22faf03",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "pan=\"3\">Qualitative volatility</td><td>High</td><td>-10%</td><td>0%</td><td>10%</td><td>20%</td><td>30%</td><td>0.80</td><td>0.89</td><td>0.98</td></tr><tr><td>Medium</td><td>-20%</td><td>-10%</td><td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "55b16bfbff50f46f",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">10%</td><td>20%</td><td>30%</td><td>0.80</td><td>0.89</td><td>0.98</td></tr><tr><td>Medium</td><td>-20%</td><td>-10%</td><td>0%</td><td>10%</td><td>20%</td><td>0.71</td><td>0.80</td><td>0.89</td></tr",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4688451188102050",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "20%</td><td>30%</td><td>0.80</td><td>0.89</td><td>0.98</td></tr><tr><td>Medium</td><td>-20%</td><td>-10%</td><td>0%</td><td>10%</td><td>20%</td><td>0.71</td><td>0.80</td><td>0.89</td></tr><tr><td>Low<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "78d0dc6b0823cb44",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td><td>0.80</td><td>0.89</td><td>0.98</td></tr><tr><td>Medium</td><td>-20%</td><td>-10%</td><td>0%</td><td>10%</td><td>20%</td><td>0.71</td><td>0.80</td><td>0.89</td></tr><tr><td>Low</td><td>-30%<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "8a74e07e257d0e92",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0.80</td><td>0.89</td><td>0.98</td></tr><tr><td>Medium</td><td>-20%</td><td>-10%</td><td>0%</td><td>10%</td><td>20%</td><td>0.71</td><td>0.80</td><td>0.89</td></tr><tr><td>Low</td><td>-30%</td><td>-20",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4d18b20ee0fec4f2",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">0.89</td><td>0.98</td></tr><tr><td>Medium</td><td>-20%</td><td>-10%</td><td>0%</td><td>10%</td><td>20%</td><td>0.71</td><td>0.80</td><td>0.89</td></tr><tr><td>Low</td><td>-30%</td><td>-20%</td><td>-1",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "825bbdfa9eaadf3a",
        "value": -0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>0%</td><td>10%</td><td>20%</td><td>0.71</td><td>0.80</td><td>0.89</td></tr><tr><td>Low</td><td>-30%</td><td>-20%</td><td>-10%</td><td>0%</td><td>10%</td><td>0.62</td><td>0.71</td><td>0.80</td></t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "303a72be4845d366",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>10%</td><td>20%</td><td>0.71</td><td>0.80</td><td>0.89</td></tr><tr><td>Low</td><td>-30%</td><td>-20%</td><td>-10%</td><td>0%</td><td>10%</td><td>0.62</td><td>0.71</td><td>0.80</td></tr></table> So",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "88a4bf7fb358430e",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>20%</td><td>0.71</td><td>0.80</td><td>0.89</td></tr><tr><td>Low</td><td>-30%</td><td>-20%</td><td>-10%</td><td>0%</td><td>10%</td><td>0.62</td><td>0.71</td><td>0.80</td></tr></table> Source: BofA Gl",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "fdf351f6d3a478ba",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">0.71</td><td>0.80</td><td>0.89</td></tr><tr><td>Low</td><td>-30%</td><td>-20%</td><td>-10%</td><td>0%</td><td>10%</td><td>0.62</td><td>0.71</td><td>0.80</td></tr></table> Source: BofA Global Research",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "ac6c5189d794a9a3",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>0.80</td><td>0.89</td></tr><tr><td>Low</td><td>-30%</td><td>-20%</td><td>-10%</td><td>0%</td><td>10%</td><td>0.62</td><td>0.71</td><td>0.80</td></tr></table> Source: BofA Global Research estimates.",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c892b0d2b257854c",
        "value": 3800.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "Company, Visible Alpha. Estimates by BofA Global Research ## Exhibit 2: DCF Analysis We calculate ¥3,800 price objective based on 12- year DCF <table><tr><td></td><td>FY3/26E</td><td>FY3/27E</td><td>F",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "5aeeeb8d557b36d5",
        "value": 0.7909999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Gross margin</td><td>79.1%</td><td>78.6%</td><td>77.6%</td><td>75.1%</td><td>72.4%</td><td>70.3%</td><td>68.9%</td><td>67",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "93984abf0367f873",
        "value": 0.7859999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Gross margin</td><td>79.1%</td><td>78.6%</td><td>77.6%</td><td>75.1%</td><td>72.4%</td><td>70.3%</td><td>68.9%</td><td>67.6%</td><td>66",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "2a57904177709df9",
        "value": 0.7759999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td></td><td></td><td></td><td></td></tr><tr><td>Gross margin</td><td>79.1%</td><td>78.6%</td><td>77.6%</td><td>75.1%</td><td>72.4%</td><td>70.3%</td><td>68.9%</td><td>67.6%</td><td>66.2%</td><td>65",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d0b868828d2ec614",
        "value": 0.7509999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td><td></td><td></td></tr><tr><td>Gross margin</td><td>79.1%</td><td>78.6%</td><td>77.6%</td><td>75.1%</td><td>72.4%</td><td>70.3%</td><td>68.9%</td><td>67.6%</td><td>66.2%</td><td>65.2%</td></tr><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "190093c1ef8fc0f9",
        "value": 0.7240000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td></tr><tr><td>Gross margin</td><td>79.1%</td><td>78.6%</td><td>77.6%</td><td>75.1%</td><td>72.4%</td><td>70.3%</td><td>68.9%</td><td>67.6%</td><td>66.2%</td><td>65.2%</td></tr><tr><td>SG&amp;",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "84b0e81033bf418e",
        "value": 0.703,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Gross margin</td><td>79.1%</td><td>78.6%</td><td>77.6%</td><td>75.1%</td><td>72.4%</td><td>70.3%</td><td>68.9%</td><td>67.6%</td><td>66.2%</td><td>65.2%</td></tr><tr><td>SG&amp;amp;A</td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9ac5045e8e863767",
        "value": 0.6890000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "margin</td><td>79.1%</td><td>78.6%</td><td>77.6%</td><td>75.1%</td><td>72.4%</td><td>70.3%</td><td>68.9%</td><td>67.6%</td><td>66.2%</td><td>65.2%</td></tr><tr><td>SG&amp;amp;A</td><td>50.5%</td><td>5",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d25f4383a4938b29",
        "value": 0.6759999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>79.1%</td><td>78.6%</td><td>77.6%</td><td>75.1%</td><td>72.4%</td><td>70.3%</td><td>68.9%</td><td>67.6%</td><td>66.2%</td><td>65.2%</td></tr><tr><td>SG&amp;amp;A</td><td>50.5%</td><td>51.7%</td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "0188c693589db32b",
        "value": 0.662,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>78.6%</td><td>77.6%</td><td>75.1%</td><td>72.4%</td><td>70.3%</td><td>68.9%</td><td>67.6%</td><td>66.2%</td><td>65.2%</td></tr><tr><td>SG&amp;amp;A</td><td>50.5%</td><td>51.7%</td><td>50.1%</td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "f4c97f8f970df6b4",
        "value": 0.652,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>77.6%</td><td>75.1%</td><td>72.4%</td><td>70.3%</td><td>68.9%</td><td>67.6%</td><td>66.2%</td><td>65.2%</td></tr><tr><td>SG&amp;amp;A</td><td>50.5%</td><td>51.7%</td><td>50.1%</td><td>48.0%</td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "dc539dbe82afa320",
        "value": 0.505,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "70.3%</td><td>68.9%</td><td>67.6%</td><td>66.2%</td><td>65.2%</td></tr><tr><td>SG&amp;amp;A</td><td>50.5%</td><td>51.7%</td><td>50.1%</td><td>48.0%</td><td>46.1%</td><td>44.1%</td><td>42.3%</td><td>41",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c7fe4a2d34cbf4c6",
        "value": 0.517,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "68.9%</td><td>67.6%</td><td>66.2%</td><td>65.2%</td></tr><tr><td>SG&amp;amp;A</td><td>50.5%</td><td>51.7%</td><td>50.1%</td><td>48.0%</td><td>46.1%</td><td>44.1%</td><td>42.3%</td><td>41.0%</td><td>39",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "f1b38068e3c7cb1e",
        "value": 0.501,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "67.6%</td><td>66.2%</td><td>65.2%</td></tr><tr><td>SG&amp;amp;A</td><td>50.5%</td><td>51.7%</td><td>50.1%</td><td>48.0%</td><td>46.1%</td><td>44.1%</td><td>42.3%</td><td>41.0%</td><td>39.8%</td><td>38",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "58e7ad5832bd9f17",
        "value": 0.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "66.2%</td><td>65.2%</td></tr><tr><td>SG&amp;amp;A</td><td>50.5%</td><td>51.7%</td><td>50.1%</td><td>48.0%</td><td>46.1%</td><td>44.1%</td><td>42.3%</td><td>41.0%</td><td>39.8%</td><td>38.6%</td></tr><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "bb67231e161aa156",
        "value": 0.461,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "65.2%</td></tr><tr><td>SG&amp;amp;A</td><td>50.5%</td><td>51.7%</td><td>50.1%</td><td>48.0%</td><td>46.1%</td><td>44.1%</td><td>42.3%</td><td>41.0%</td><td>39.8%</td><td>38.6%</td></tr><tr><td>R&amp;a",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "28e647eef4c2b8c6",
        "value": 0.441,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>SG&amp;amp;A</td><td>50.5%</td><td>51.7%</td><td>50.1%</td><td>48.0%</td><td>46.1%</td><td>44.1%</td><td>42.3%</td><td>41.0%</td><td>39.8%</td><td>38.6%</td></tr><tr><td>R&amp;amp;D</td><td>2",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "2d355541889d57e5",
        "value": 0.423,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "p;amp;A</td><td>50.5%</td><td>51.7%</td><td>50.1%</td><td>48.0%</td><td>46.1%</td><td>44.1%</td><td>42.3%</td><td>41.0%</td><td>39.8%</td><td>38.6%</td></tr><tr><td>R&amp;amp;D</td><td>22.8%</td><td>2",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "0358a14e67b5a2ed",
        "value": 0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>50.5%</td><td>51.7%</td><td>50.1%</td><td>48.0%</td><td>46.1%</td><td>44.1%</td><td>42.3%</td><td>41.0%</td><td>39.8%</td><td>38.6%</td></tr><tr><td>R&amp;amp;D</td><td>22.8%</td><td>21.7%</td><td>2",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c1ae9a249aa7fa83",
        "value": 0.39799999999999996,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>51.7%</td><td>50.1%</td><td>48.0%</td><td>46.1%</td><td>44.1%</td><td>42.3%</td><td>41.0%</td><td>39.8%</td><td>38.6%</td></tr><tr><td>R&amp;amp;D</td><td>22.8%</td><td>21.7%</td><td>21.0%</td><td>2",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4eca1888220db864",
        "value": 0.386,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>50.1%</td><td>48.0%</td><td>46.1%</td><td>44.1%</td><td>42.3%</td><td>41.0%</td><td>39.8%</td><td>38.6%</td></tr><tr><td>R&amp;amp;D</td><td>22.8%</td><td>21.7%</td><td>21.0%</td><td>20.4%</td><td>1",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fcd3fb7fc530221c",
        "value": 0.228,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">44.1%</td><td>42.3%</td><td>41.0%</td><td>39.8%</td><td>38.6%</td></tr><tr><td>R&amp;amp;D</td><td>22.8%</td><td>21.7%</td><td>21.0%</td><td>20.4%</td><td>19.2%</td><td>18.0%</td><td>17.2%</td><td>16",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "6ab1ddbc93ef00af",
        "value": 0.217,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">42.3%</td><td>41.0%</td><td>39.8%</td><td>38.6%</td></tr><tr><td>R&amp;amp;D</td><td>22.8%</td><td>21.7%</td><td>21.0%</td><td>20.4%</td><td>19.2%</td><td>18.0%</td><td>17.2%</td><td>16.6%</td><td>17",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ed68da5a9a523dcf",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">41.0%</td><td>39.8%</td><td>38.6%</td></tr><tr><td>R&amp;amp;D</td><td>22.8%</td><td>21.7%</td><td>21.0%</td><td>20.4%</td><td>19.2%</td><td>18.0%</td><td>17.2%</td><td>16.6%</td><td>17.0%</td><td>16",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "1c8fd606de644176",
        "value": 0.204,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">39.8%</td><td>38.6%</td></tr><tr><td>R&amp;amp;D</td><td>22.8%</td><td>21.7%</td><td>21.0%</td><td>20.4%</td><td>19.2%</td><td>18.0%</td><td>17.2%</td><td>16.6%</td><td>17.0%</td><td>16.9%</td></tr><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "005895e6abc7ac1d",
        "value": 0.192,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">38.6%</td></tr><tr><td>R&amp;amp;D</td><td>22.8%</td><td>21.7%</td><td>21.0%</td><td>20.4%</td><td>19.2%</td><td>18.0%</td><td>17.2%</td><td>16.6%</td><td>17.0%</td><td>16.9%</td></tr><tr><td>Operati",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "83846465a2931b12",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>R&amp;amp;D</td><td>22.8%</td><td>21.7%</td><td>21.0%</td><td>20.4%</td><td>19.2%</td><td>18.0%</td><td>17.2%</td><td>16.6%</td><td>17.0%</td><td>16.9%</td></tr><tr><td>Operating margin</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "f482f034ab41431c",
        "value": 0.172,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "p;amp;D</td><td>22.8%</td><td>21.7%</td><td>21.0%</td><td>20.4%</td><td>19.2%</td><td>18.0%</td><td>17.2%</td><td>16.6%</td><td>17.0%</td><td>16.9%</td></tr><tr><td>Operating margin</td><td>7.2%</td><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fa66846fbc649159",
        "value": 0.166,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>22.8%</td><td>21.7%</td><td>21.0%</td><td>20.4%</td><td>19.2%</td><td>18.0%</td><td>17.2%</td><td>16.6%</td><td>17.0%</td><td>16.9%</td></tr><tr><td>Operating margin</td><td>7.2%</td><td>6.9%</td><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "584aea61f1980788",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>21.7%</td><td>21.0%</td><td>20.4%</td><td>19.2%</td><td>18.0%</td><td>17.2%</td><td>16.6%</td><td>17.0%</td><td>16.9%</td></tr><tr><td>Operating margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a41f8e8d9aa61697",
        "value": 0.16899999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>21.0%</td><td>20.4%</td><td>19.2%</td><td>18.0%</td><td>17.2%</td><td>16.6%</td><td>17.0%</td><td>16.9%</td></tr><tr><td>Operating margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "2a963025f569f2a0",
        "value": 0.07200000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>17.2%</td><td>16.6%</td><td>17.0%</td><td>16.9%</td></tr><tr><td>Operating margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td><td>9.1%</td><td>10.2%</td><td>10.8%</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "f02961ddab46e3b7",
        "value": 0.069,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2%</td><td>16.6%</td><td>17.0%</td><td>16.9%</td></tr><tr><td>Operating margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td><td>9.1%</td><td>10.2%</td><td>10.8%</td><td>10.2%</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ec6dec14d1ff5728",
        "value": 0.075,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".6%</td><td>17.0%</td><td>16.9%</td></tr><tr><td>Operating margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td><td>9.1%</td><td>10.2%</td><td>10.8%</td><td>10.2%</td><td>10.4%<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3576e692c4dc4ca1",
        "value": 0.077,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7.0%</td><td>16.9%</td></tr><tr><td>Operating margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td><td>9.1%</td><td>10.2%</td><td>10.8%</td><td>10.2%</td><td>10.4%</td></tr><tr>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "51db019bbfe68cdc",
        "value": 0.081,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "16.9%</td></tr><tr><td>Operating margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td><td>9.1%</td><td>10.2%</td><td>10.8%</td><td>10.2%</td><td>10.4%</td></tr><tr><td>Effective",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c8dc776e155568eb",
        "value": 0.091,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>Operating margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td><td>9.1%</td><td>10.2%</td><td>10.8%</td><td>10.2%</td><td>10.4%</td></tr><tr><td>Effective tax rate</td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d4f494eb380213b9",
        "value": 0.102,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rating margin</td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td><td>9.1%</td><td>10.2%</td><td>10.8%</td><td>10.2%</td><td>10.4%</td></tr><tr><td>Effective tax rate</td><td>29.2%</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ed242535d07ea84f",
        "value": 0.10800000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>7.2%</td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td><td>9.1%</td><td>10.2%</td><td>10.8%</td><td>10.2%</td><td>10.4%</td></tr><tr><td>Effective tax rate</td><td>29.2%</td><td>21.3%</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c442c2156714595e",
        "value": 0.102,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>6.9%</td><td>7.5%</td><td>7.7%</td><td>8.1%</td><td>9.1%</td><td>10.2%</td><td>10.8%</td><td>10.2%</td><td>10.4%</td></tr><tr><td>Effective tax rate</td><td>29.2%</td><td>21.3%</td><td>26.3%</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "cdf46b6a13f934a4",
        "value": 0.10400000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>7.5%</td><td>7.7%</td><td>8.1%</td><td>9.1%</td><td>10.2%</td><td>10.8%</td><td>10.2%</td><td>10.4%</td></tr><tr><td>Effective tax rate</td><td>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3d3fda1863c3122d",
        "value": 0.292,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>10.2%</td><td>10.8%</td><td>10.2%</td><td>10.4%</td></tr><tr><td>Effective tax rate</td><td>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td>20",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "bebeea7d40cc7154",
        "value": 0.213,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>10.8%</td><td>10.2%</td><td>10.4%</td></tr><tr><td>Effective tax rate</td><td>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td></",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "bfe770554e6a8c6c",
        "value": 0.263,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>10.2%</td><td>10.4%</td></tr><tr><td>Effective tax rate</td><td>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td></td><td>28.4%</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4de741328720773e",
        "value": 0.201,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>10.4%</td></tr><tr><td>Effective tax rate</td><td>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td></td><td>28.4%</td></tr><tr><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "07dbde50be4a11db",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td></tr><tr><td>Effective tax rate</td><td>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td></td><td>28.4%</td></tr><tr><td>Net margin</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "355d4e2e2b723e62",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Effective tax rate</td><td>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td></td><td>28.4%</td></tr><tr><td>Net margin</td><td>5.7%</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c5d3f006f9dc3e97",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ax rate</td><td>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td></td><td>28.4%</td></tr><tr><td>Net margin</td><td>5.7%</td><td>5.9%</td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "879d9c088c1458e7",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>29.2%</td><td>21.3%</td><td>26.3%</td><td>20.1%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td></td><td>28.4%</td></tr><tr><td>Net margin</td><td>5.7%</td><td>5.9%</td><td>5.9%</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fb282f528df484e9",
        "value": 0.284,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>26.3%</td><td>20.1%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td></td><td>28.4%</td></tr><tr><td>Net margin</td><td>5.7%</td><td>5.9%</td><td>5.9%</td><td>6.6%</td><td>6.9%</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "86e41a62f033331f",
        "value": 0.057,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>20.0%</td><td>20.0%</td><td>20.0%</td><td></td><td>28.4%</td></tr><tr><td>Net margin</td><td>5.7%</td><td>5.9%</td><td>5.9%</td><td>6.6%</td><td>6.9%</td><td>7.6%</td><td>8.5%</td><td>9.0%</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "94398e8d68630b68",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",000</td><td>35,100</td><td>42,100</td><td>46,300</td></tr><tr><td>Risk adjusted</td><td>P3</td><td>50%</td><td></td><td>500</td><td>2,500</td><td>5,000</td><td>9,000</td><td>13,500</td><td>17,600</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "fe404dfc3967f0e2",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",000</td><td>18,000</td><td>23,400</td><td>28,100</td></tr><tr><td>Risk adjusted</td><td>P2</td><td>20%</td><td></td><td></td><td></td><td></td><td>1,200</td><td>2,400</td><td>3,600</td><td>4,700</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a1b737a6e8a0f4b2",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "00</td><td>35,100</td><td>52,700</td><td>68,500</td></tr><tr><td>Risk adjusted</td><td>P2/3</td><td>30%</td><td></td><td></td><td></td><td>600</td><td>2,600</td><td>5,900</td><td>10,500</td><td>15,800",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a83d5f17763dd5ab",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",500</td><td>48,000</td><td>66,600</td><td>83,100</td></tr><tr><td>Risk adjusted</td><td>P2</td><td>20%</td><td></td><td></td><td></td><td>600</td><td>2,500</td><td>5,700</td><td>9,600</td><td>13,300<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "31b1482410d860da",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "00</td><td>15,000</td><td>20,700</td><td>25,800</td></tr><tr><td>Risk adjusted</td><td>P1/2</td><td>10%</td><td></td><td></td><td></td><td>100</td><td>400</td><td>900</td><td>1,500</td><td>2,100</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "ae92d8c620c708c7",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>4,300</td><td>5,200</td><td>5,700</td><td>6,000</td></tr><tr><td>Risk adjusted</td><td>P2</td><td>20%</td><td></td><td></td><td>100</td><td>200</td><td>400</td><td>700</td><td>900</td><td>1,000</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "610a748a8bb7e65e",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>5,600</td><td>6,200</td><td>6,500</td><td>6,500</td></tr><tr><td>Risk adjusted</td><td>P2</td><td>50%</td><td>200</td><td>600</td><td>1,200</td><td>1,800</td><td>2,400</td><td>2,800</td><td>3,100</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "d3aefa839de200a1",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "00</td><td>14,000</td><td>16,800</td><td>18,500</td></tr><tr><td>Risk adjusted</td><td>P1/2</td><td>20%</td><td></td><td></td><td>200</td><td>700</td><td>1,400</td><td>2,200</td><td>2,800</td><td>3,40",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "baff56ae146f899d",
        "value": 0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e also taking into account valuations such as P/E and P/B. Our DCF assumptions are risk - free rate 1.5%, equity risk premium 5.5%, terminal growth 1% and tax rate 40%. Individual company FCF risk is ",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "8f4a5373f775840e",
        "value": 0.055,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "valuations such as P/E and P/B. Our DCF assumptions are risk - free rate 1.5%, equity risk premium 5.5%, terminal growth 1% and tax rate 40%. Individual company FCF risk is reflected in the stock beta",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "01356bdfb869d152",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "E and P/B. Our DCF assumptions are risk - free rate 1.5%, equity risk premium 5.5%, terminal growth 1% and tax rate 40%. Individual company FCF risk is reflected in the stock beta, which takes into ac",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "d1d2687532d56493",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "CF assumptions are risk - free rate 1.5%, equity risk premium 5.5%, terminal growth 1% and tax rate 40%. Individual company FCF risk is reflected in the stock beta, which takes into account quantitati",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "5fb2a93ff69da5dc",
        "value": 0.066,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "wo- year adjusted beta is 0.89, and we base our price objective on a stock beta of 1.06 and WACC of 6.6%. Our PO corresponds to a P/E of 20x or FY3/27 EPS forecast. Downside risks are (1) mainstay dru",
        "provenance": {
          "page": 7
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 0,
      "tables_count": 0,
      "numerical_data_count": 156,
      "passages_count": 104,
      "entities_count": 20
    }
  }
}